Zobrazeno 1 - 3
of 3
pro vyhledávání: '"SWITCH Res Grp"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F., Visser, L.G., Schmitz, K.S., Geers, D., Bogers, S., Haren, E. van, Koopmans, M.P.G., Dalm, V.A.S.H., Kootstra, N.A., Huckriede, A.L.W., Akkerman, R., Beukema, M., Lafeber, M., Baarle, D. van, Vries, R.D. de, Kuy, P.H.M. van der, GeurtsvanKessel, C.H., SWITCH Res Grp
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3). Oxford University Press
Clinical Infectious Diseases, 76(3), e533-e536. OXFORD UNIV PRESS INC
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3):ciac495, e533-e536. Oxford University Press
Clinical infectious diseases, 76(3), e533-e536. Oxford University Press
Clinical Infectious Diseases, 76(3), e533-e536. OXFORD UNIV PRESS INC
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3):ciac495, e533-e536. Oxford University Press
Clinical infectious diseases, 76(3), e533-e536. Oxford University Press
The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2–specific binding antibodies, neutralizing antibodies, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28486eec836495dfd683d7e47c56c68
https://doi.org/10.1093/cid/ciac495
https://doi.org/10.1093/cid/ciac495
Autor:
Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F., Visser, L.G., Geers, D., Schmitz, K.S., Garrido, H.M.G., Koopmans, M.P.G., Dalm, V.A.S.H., Kootstra, N.A., Huckriede, A.L.W., Lafeber, M., Baarle, D. van, GeurtsvanKessel, C.H., Vries, R.D. de, Kuy, P.H.M. van der, SWITCH Res Grp
Publikováno v:
New England Journal of Medicine, 386(10), 951-963. Massachussetts Medical Society
The New England journal of medicine, 386(10), 951-963. MASSACHUSETTS MEDICAL SOC
New England journal of medicine, 386(10), 951-963. Massachussetts Medical Society
The New England Journal of Medicine
New England Journal of Medicine, 386, 951-963. MASSACHUSETTS MEDICAL SOC
The New England journal of medicine, 386(10), 951-963. MASSACHUSETTS MEDICAL SOC
New England journal of medicine, 386(10), 951-963. Massachussetts Medical Society
The New England Journal of Medicine
New England Journal of Medicine, 386, 951-963. MASSACHUSETTS MEDICAL SOC
BACKGROUND: The Ad26.COV2.S vaccine, which was approved as a single-shot immunization regimen, has been shown to be effective against severe coronavirus disease 2019. However, this vaccine induces lower severe acute respiratory syndrome coronavirus 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c533e6a2e396ec700dfcc8c219db189
http://hdl.handle.net/10029/625622
http://hdl.handle.net/10029/625622